Corporate Investor

Updated:

Kolmar Korea

Founded in 1990 by Yoon Dong-han, Kolmar Korea became the leading original design manufacturer for South Korea's cosmetics export boom, supplying formulation,...

Kolmar Korea logo

Kolmar Korea

Founded in 1990 by Yoon Dong-han, Kolmar Korea became the leading original design manufacturer for South Korea's cosmetics export boom, supplying formulation, packaging, and manufacturing for brands that drive the country's $10 billion-plus beauty trade surplus. The elder Yoon, now in his late 70s, built the group into a vertically integrated operation spanning cosmetics, pharmaceuticals through subsidiary HK Inno.N, and health-functional foods. His daughter Yoon Yeo-won runs Kolmar BNH, the health-supplement arm, and sided publicly with her father during the 2025 lawsuit against her brother Yoon Sang-hyun, the group's vice chairman and designated heir. The dispute centers on shares the founder transferred to his son years ago — a private conflict now litigated in Korean courts. Kolmar Korea deploys capital across three axes: manufacturing infrastructure, pharmaceutical R&D, and cultural philanthropy. Its Scott Township plant in Pennsylvania supplies North American beauty brands; the Wuxi factory in China's Jiangsu Province serves the domestic market and regional exports. The Seoul R&D complex houses formulation scientists who develop thousands of stock-keeping units annually for clients ranging from Amazon's private-label beauty lines to Korean indie brands scaling globally. In pharmaceuticals, HK Inno.N — formerly CJ Healthcare before Kolmar acquired it — holds the patent for K-Cab, a blockbuster gastroesophageal reflux treatment that generated over $700 million in cumulative revenue, and invests in clinical-stage biotechs through its venture arm. The firm has not disclosed an external allocation program or LP commitments to third-party funds, operating strictly as a corporate strategic investor. In September 2023, the firm joined the UN Global Compact Korea LEAD Group, a designation reserved for companies demonstrating advanced ESG reporting and sustainable supply-chain management — relevant to allocators evaluating governance maturity during a leadership dispute. Kolmar also controls the Seokoh Culture Foundation, which preserves Korean Buddhist art and holds the nationally designated Water-Moon Avalokiteshvara painting at the National Museum of Korea, and the Seoul Maritime Foundation. The Yeoju Academy in Gyeonggi Province functions as a corporate training and R&D campus. These assets sit alongside the industrial core rather than inside a family office structure — Kolmar does not operate a separate investment office or family office vehicle, and allocators seeking co-investment would interface directly with corporate treasury or HK Inno.N's strategic team. What distinguishes Kolmar Korea structurally is its operational-conglomerate architecture rather than a financial-portfolio model. The Yoon family controls the group through direct operating company ownership, not a holding company with a CIO and external allocators. The ongoing succession dispute between the founder and his son creates governance uncertainty — a friction that institutional co-investors, commercial partners, and the UNGC will monitor as leadership transitions from first to second generation. No external family office or trust structure has been disclosed that would insulate decision-making from the personal conflict.

General information

Firm type

Corporate Investor

Year founded

1990

AUM

Undisclosed

Location

Region

Asia

Country

South Korea

City

Seoul

Corporate office

12-11, Deokgogae-gil, Jeonui-myeon, Sejong, South Korea

Additional offices

61, Heolleung-ro 8-gil, Seocho-gu, Seoul, South Korea · Scott Township, Pennsylvania, USA · Wuxi, Jiangsu Province, China

Principals

Yoon Dong-han

Founder and Chairman, Kolmar Group

Yoon Sang-hyun

Vice Chairman, Kolmar Group

Yoon Yeo-won

CEO, Kolmar BNH

Sector focus

Cosmetics & Personal CarePharmaceuticalsHealth & Wellness

Frequently asked questions

Who controls investment decisions at Kolmar Korea?

Investment and capital allocation decisions are made by the founding Yoon family through direct operating company control rather than a separate investment office. Founder and Chairman Yoon Dong-han holds ultimate authority, with Vice Chairman Yoon Sang-hyun overseeing operations. The 2025 lawsuit between father and son over share ownership creates uncertainty about who will control deployment decisions during any succession transition.

Does Kolmar Korea operate a family office or external investment vehicle?

No. Kolmar Korea does not maintain a single-family office, multi-family office, or external investment arm. Capital deployment occurs through the corporate balance sheet — manufacturing plants, R&D facilities, the pharmaceutical subsidiary HK Inno.N, and cultural foundations. Allocators seeking co-investment would need to engage directly with corporate treasury or the strategic ventures team at HK Inno.N.

What is the relationship between Kolmar Korea and HK Inno.N?

HK Inno.N is Kolmar Korea's pharmaceutical subsidiary, acquired from CJ Group and formerly known as CJ Healthcare. It operates as a separate listed entity on the Korea Exchange with its own management, R&D pipeline, and venture investment activity. The subsidiary's flagship drug K-Cab treats gastroesophageal reflux disease and has generated substantial revenue, funding further clinical-stage investments.

How does the Yoon family succession dispute affect Kolmar Korea's operations?

The 2025 lawsuit filed by founder Yoon Dong-han against his son Yoon Sang-hyun seeks return of shares and signals a breakdown in the previously planned succession. Daughter Yoon Yeo-won, CEO of Kolmar BNH, has publicly aligned with her father. The dispute has introduced governance uncertainty that commercial partners and the UN Global Compact — which admitted the firm to its LEAD Group in 2023 — are likely monitoring. Korean conglomerates often resolve such disputes through negotiated settlement, but no resolution has been announced publicly.

Does Kolmar Korea make LP commitments to external funds or invest in startups?

Kolmar Korea has not disclosed any fund commitment program or LP activity in private equity, venture capital, or hedge funds. HK Inno.N, its pharmaceutical subsidiary, makes strategic venture investments in clinical-stage biotechs aligned with its therapeutic pipeline, but those are corporate venture capital deals, not blind-pool fund commitments.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on investors?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Seoul Corporate Investor profiles